Heberlig Chris 4
4 · Kiniksa Pharmaceuticals, Ltd. · Filed May 29, 2018
Insider Transaction Report
Form 4
Heberlig Chris
Exec VP & CFO10% Owner
Transactions
- Conversion
Series A Preferred Shares
2018-05-29−74,935→ 0 total→ Class B Common Shares (74,935 underlying) - Conversion
Series C Preferred Shares
2018-05-29−6,392→ 0 total→ Class A Common Shares (6,392 underlying) - Purchase
Series C Preferred Shares
2018-02-09$15.64/sh+6,392$99,995→ 6,392 total→ Class A Common Shares (6,392 underlying) - Conversion
Class B Common Shares
2018-05-29+74,935→ 440,920 total→ Class A Common Shares (74,935 underlying) - Conversion
Class A Common Shares
2018-05-29+6,392→ 42,991 total
Holdings
- 36,598(indirect: By Trust)
Class A Common Shares
Footnotes (4)
- [F1]Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.
- [F2]Reflects the 1-for-2.73235 share consolidation effected May 11, 2018.
- [F3]Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.
- [F4]Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.